IN2014DN08598A - - Google Patents
Info
- Publication number
- IN2014DN08598A IN2014DN08598A IN8598DEN2014A IN2014DN08598A IN 2014DN08598 A IN2014DN08598 A IN 2014DN08598A IN 8598DEN2014 A IN8598DEN2014 A IN 8598DEN2014A IN 2014DN08598 A IN2014DN08598 A IN 2014DN08598A
- Authority
- IN
- India
- Prior art keywords
- cmax
- agent
- caverage
- ratio
- hydrophilicity
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1206628.8A GB201206628D0 (en) | 2012-04-16 | 2012-04-16 | Subcutaneous administration of PEGylated blood clotting factors |
| GBGB1213712.1A GB201213712D0 (en) | 2012-08-01 | 2012-08-01 | Modified therapeutic agents |
| GBGB1214985.2A GB201214985D0 (en) | 2012-08-22 | 2012-08-22 | Modified therapeutic agents |
| PCT/EP2013/057928 WO2013156488A2 (en) | 2012-04-16 | 2013-04-16 | Optimised subcutaneous therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08598A true IN2014DN08598A (OSRAM) | 2015-05-22 |
Family
ID=48190923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8598DEN2014 IN2014DN08598A (OSRAM) | 2012-04-16 | 2013-04-16 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150086524A1 (OSRAM) |
| EP (1) | EP2838566A2 (OSRAM) |
| JP (3) | JP2015512927A (OSRAM) |
| KR (1) | KR102137290B1 (OSRAM) |
| CN (1) | CN104411335A (OSRAM) |
| AP (1) | AP2014008049A0 (OSRAM) |
| AU (3) | AU2013248296A1 (OSRAM) |
| BR (1) | BR112014025737A2 (OSRAM) |
| CA (1) | CA2869993C (OSRAM) |
| CL (1) | CL2014002773A1 (OSRAM) |
| CO (1) | CO7151496A2 (OSRAM) |
| CR (1) | CR20140475A (OSRAM) |
| EA (1) | EA033469B1 (OSRAM) |
| EC (1) | ECSP14023048A (OSRAM) |
| GB (3) | GB2516388A (OSRAM) |
| GE (1) | GEP201706716B (OSRAM) |
| HK (1) | HK1200695A1 (OSRAM) |
| IL (1) | IL235129B (OSRAM) |
| IN (1) | IN2014DN08598A (OSRAM) |
| MD (1) | MD20140123A2 (OSRAM) |
| MX (2) | MX2014012512A (OSRAM) |
| MY (1) | MY190257A (OSRAM) |
| NI (1) | NI201400122A (OSRAM) |
| NZ (1) | NZ701205A (OSRAM) |
| PE (1) | PE20150226A1 (OSRAM) |
| PH (1) | PH12014502314B1 (OSRAM) |
| SG (1) | SG11201406492YA (OSRAM) |
| WO (1) | WO2013156488A2 (OSRAM) |
| ZA (1) | ZA201407370B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498815B (zh) * | 2013-12-30 | 2022-07-22 | 江苏众红生物工程创药研究院有限公司 | 重组人激肽释放酶的化学修饰物及其应用 |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| FR3034669B1 (fr) * | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| WO2016198641A1 (en) * | 2015-06-12 | 2016-12-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Injectable composition of factor vii and fillers |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| CN109998994B (zh) * | 2018-02-13 | 2021-12-07 | 四川大学 | 包含药物的柔性脂质体及其制备方法 |
| CN114929261A (zh) | 2020-02-17 | 2022-08-19 | 生物测试股份公司 | 凝血因子viii的皮下施用 |
| CN115443147A (zh) * | 2020-04-23 | 2022-12-06 | 伊莱利利公司 | 抗体的皮下吸收和生物利用度 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479268A (en) | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| CH596313A5 (OSRAM) | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
| US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| WO1990015628A1 (en) * | 1989-06-14 | 1990-12-27 | Cetus Corporation | Polymer/antibiotic conjugate |
| AU5098193A (en) | 1992-09-01 | 1994-03-29 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
| US5580981A (en) | 1992-09-28 | 1996-12-03 | Research Corporation Technologies, Inc. | Azahydroxybenzotriazoles and derivatives thereof for peptide coupling reactions |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| JPH0892294A (ja) * | 1994-09-29 | 1996-04-09 | Teijin Ltd | ヒト活性化プロテインｃ誘導体 |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| JPH08325270A (ja) * | 1995-05-31 | 1996-12-10 | Bristol Myers Squibb Co | β−ラクタマーゼに対するポリマープロドラッグおよびその使用 |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| JP2001508783A (ja) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | Ｐｅｇ化法 |
| AU2605099A (en) * | 1998-02-25 | 1999-09-15 | Micrologix Biotech, Inc. | Indolicidin and cationic peptides conjugated with polymers |
| EP1982732A3 (en) * | 2000-02-11 | 2011-06-08 | Bayer HealthCare LLC | Factor VII or VIIA-like conjugates |
| AU2001256148A1 (en) | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Subcutaneous administration of coagulation factor vii |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| KR101186140B1 (ko) * | 2002-06-21 | 2012-09-27 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 페길화된 인자 ｖｉｉ 글리코형태 |
| DE60336555D1 (de) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
| DK1596887T3 (da) * | 2003-02-26 | 2022-06-20 | Nektar Therapeutics | Polymer-Faktor VIII-konjugat |
| ES2512499T3 (es) * | 2003-04-08 | 2014-10-24 | Yeda Research And Development Co., Ltd. | Fármacos pegilados reversibles |
| US20130137157A1 (en) * | 2003-04-09 | 2013-05-30 | Novo Nordisk A/S | Glycopegylated factor vii and factor viia |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| JPWO2005084679A1 (ja) | 2004-03-04 | 2007-11-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ベンズアミジン誘導体含有組成物及びベンズアミジン誘導体の安定化方法 |
| ES2390082T5 (es) * | 2004-06-30 | 2018-01-19 | Nektar Therapeutics | Conjugados de resto de Factor IX y polímeros |
| EP1778838A2 (en) | 2004-08-02 | 2007-05-02 | Novo Nordisk Health Care AG | Conjugation of fvii |
| EP2975135A1 (en) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| AU2006280932A1 (en) * | 2005-08-19 | 2007-02-22 | Novo Nordisk A/S | Glycopegylated factor VII and factor Vila |
| CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
| ES2655639T3 (es) | 2006-12-15 | 2018-02-21 | Baxalta GmbH | Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada |
| CN101678119B (zh) * | 2006-12-27 | 2014-02-12 | 尼克塔治疗公司 | 具有可释放的键合的血管性血友病因子-和因子ⅷ-聚合物轭合物 |
| WO2008081024A1 (en) | 2007-01-03 | 2008-07-10 | Novo Nordisk Health Care Ag | Subcutaneous administration of coagulation factor viia-related popypeptdes |
| WO2008119815A1 (en) * | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
| NZ593611A (en) | 2007-04-13 | 2012-06-29 | Catalyst Biosciences Inc | Modified factor vii polypeptides and uses thereof |
| EP2014299A1 (en) | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor VII |
| CN101820920B (zh) | 2007-10-09 | 2014-08-06 | 宝力泰锐克斯有限公司 | 新的缀合蛋白质和肽 |
| ES2403413T3 (es) | 2007-10-16 | 2013-05-17 | Pharmacyclics, Inc. | Manufactura, composiciones y usos del modulador del factor de coagulación Vlla |
| RU2573587C2 (ru) | 2008-02-27 | 2016-01-20 | Ново Нордиск А/С | Конъюгированные молекулы фактора viii |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| JP2011517950A (ja) * | 2008-04-16 | 2011-06-23 | バイエル・ヘルスケア・エルエルシー | 第ｉｘ因子の部位特異的修飾 |
| CA2722169A1 (en) * | 2008-04-24 | 2009-10-29 | Celtic Pharma Peg Ltd. | Factor ix conjugates with extended half-lives |
| US20110112029A1 (en) * | 2008-05-23 | 2011-05-12 | Novo Nordisk Health Care Ag | Low viscosity compositions comprising a pegylated gla-domain containing protein |
| DK2326349T3 (en) | 2008-07-21 | 2015-05-26 | Polytherics Ltd | Novel Reagents and Methods for Conjugation of Biological Molecules |
| WO2010045321A2 (en) * | 2008-10-15 | 2010-04-22 | Baxter International Inc. | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
| KR101929641B1 (ko) * | 2008-10-17 | 2018-12-14 | 박스알타 인코퍼레이티드 | 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자 |
| WO2010083536A1 (en) * | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
| TWI537006B (zh) * | 2009-07-27 | 2016-06-11 | 巴克斯歐塔公司 | 凝血蛋白接合物 |
| CN105524164A (zh) * | 2010-02-16 | 2016-04-27 | 诺沃—诺迪斯克有限公司 | 具有降低的vwf结合的因子viii分子 |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| ES2731626T3 (es) * | 2010-07-30 | 2019-11-18 | Baxalta Inc | Catalizadores nucleofílicos para enlace oxima |
| WO2012088123A1 (en) * | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Polymer-factor vii moiety conjugates |
-
2013
- 2013-04-16 JP JP2015504987A patent/JP2015512927A/ja active Pending
- 2013-04-16 EA EA201491702A patent/EA033469B1/ru unknown
- 2013-04-16 AU AU2013248296A patent/AU2013248296A1/en not_active Abandoned
- 2013-04-16 AP AP2014008049A patent/AP2014008049A0/xx unknown
- 2013-04-16 PE PE2014001639A patent/PE20150226A1/es active IP Right Grant
- 2013-04-16 GB GB1418864.3A patent/GB2516388A/en not_active Withdrawn
- 2013-04-16 GB GBGB1910184.9A patent/GB201910184D0/en not_active Ceased
- 2013-04-16 MY MYPI2014002900A patent/MY190257A/en unknown
- 2013-04-16 GE GEAP201313632A patent/GEP201706716B/en unknown
- 2013-04-16 GB GBGB1910190.6A patent/GB201910190D0/en not_active Ceased
- 2013-04-16 WO PCT/EP2013/057928 patent/WO2013156488A2/en active Application Filing
- 2013-04-16 MX MX2014012512A patent/MX2014012512A/es unknown
- 2013-04-16 CA CA2869993A patent/CA2869993C/en active Active
- 2013-04-16 SG SG11201406492YA patent/SG11201406492YA/en unknown
- 2013-04-16 MD MD20140123A patent/MD20140123A2/ro unknown
- 2013-04-16 US US14/394,437 patent/US20150086524A1/en not_active Abandoned
- 2013-04-16 KR KR1020147031042A patent/KR102137290B1/ko active Active
- 2013-04-16 CN CN201380027958.3A patent/CN104411335A/zh active Pending
- 2013-04-16 EP EP13719043.5A patent/EP2838566A2/en active Pending
- 2013-04-16 NZ NZ701205A patent/NZ701205A/en not_active IP Right Cessation
- 2013-04-16 IL IL235129A patent/IL235129B/en unknown
- 2013-04-16 IN IN8598DEN2014 patent/IN2014DN08598A/en unknown
- 2013-04-16 BR BR112014025737A patent/BR112014025737A2/pt not_active Application Discontinuation
- 2013-04-16 HK HK15100881.5A patent/HK1200695A1/xx unknown
-
2014
- 2014-10-10 ZA ZA2014/07370A patent/ZA201407370B/en unknown
- 2014-10-14 CR CR20140475A patent/CR20140475A/es unknown
- 2014-10-15 CL CL2014002773A patent/CL2014002773A1/es unknown
- 2014-10-15 NI NI201400122A patent/NI201400122A/es unknown
- 2014-10-15 PH PH12014502314A patent/PH12014502314B1/en unknown
- 2014-10-16 EC ECIEPI201423048A patent/ECSP14023048A/es unknown
- 2014-10-16 MX MX2020014208A patent/MX2020014208A/es unknown
- 2014-11-14 CO CO14252826A patent/CO7151496A2/es unknown
-
2017
- 2017-08-30 US US15/691,090 patent/US11351112B2/en active Active
- 2017-09-06 JP JP2017171545A patent/JP6550107B2/ja active Active
-
2018
- 2018-01-05 AU AU2018200111A patent/AU2018200111B2/en not_active Ceased
-
2019
- 2019-04-05 JP JP2019073048A patent/JP2019131593A/ja active Pending
-
2020
- 2020-02-06 AU AU2020200842A patent/AU2020200842A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08598A (OSRAM) | ||
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| AU2016204185A1 (en) | Methods of administering beta7 integrin antagonists | |
| UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| IN2012DN02137A (OSRAM) | ||
| EP4360621A3 (en) | Formulations of bendamustine | |
| MX2022006770A (es) | Dispersiones solidas de bendamustina e infusion continua. | |
| MX337464B (es) | Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer. | |
| MX348418B (es) | Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada. | |
| BR112013001462B8 (pt) | Composições | |
| SG194753A1 (en) | Induction of il-12 using immunotherapy | |
| BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
| IN2014DN10134A (OSRAM) | ||
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| GEP20196947B (en) | Bremelanotide therapy for female sexual dysfunction | |
| UA111785C2 (uk) | Композиція для лікування бородавок та спосіб лікування бородавок | |
| UA63763U (ru) | Инъекционное средство с иммуностимулирующими и общеукрепляющими свойствами | |
| UA59175U (ru) | Способ медицинской реабилитации больных синдромом повышенной утомляемости | |
| UA69686U (ru) | Способ профилактики обострений параноидной шизофрении |